You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in the US

Feb 2011

Price: $2,400

About this Report

About this Report

Delivery method: instant download
Report format: PDF doc_pdf.png (download a sample)
Market statistics: Excel workbook doc_excel_table.png (download a sample)

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in USA with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in USA, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in USA for free:

The Consumer Health in USA market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in USA?
  • What are the major brands in USA?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Sample Analysis

EXECUTIVE SUMMARY

Consumer health industry remains vital

In 2010, the US economy showed signs of improvement and recovery. However, unemployment remained very high and fears about jobs persisted. In this economy, people turned to over-the-counter (OTC) products to treat illnesses and avoid potentially expensive visits to the doctor and prescription drugs. In a less than certain labour market, individuals continued to rely on OTC products to keep them healthy, energised and at their best. This continuing trend towards self-diagnosis and self-medication benefited the consumer health industry, which recorded another solid year of value sales growth in 2010.

Market leader hit by series of product recalls

Johnson & Johnson, the leader (in GBO terms) in OTC medication, instituted a series of major product recalls in 2010. These were issued consistently throughout the year and spanned many different product types. Many iconic OTC brands from Johnson & Johnson remained unavailable for most of the year and left consumers searching for alternative options. In place of recalled products, many of these consumers turned to private label products based on their widespread availability and endorsements from pharmacists. Johnson & Johnson, facing potentially unprecedented losses in reputation and consumer trust, began to implement steps to limit the damage, while other branded players emphasised their commitment to product quality and safety in an attempt to distance themselves from the beleaguered leader.

Private label growth continues

Private label continued to gain share and remain a threat to the major multinational and national manufacturers in 2010. Strong private label growth initially stemmed from the struggling economy, but remained strong during the slow economic recovery. Many private label manufacturers are becoming increasingly aggressive at challenging branded products by improving quality and efficacy. Furthermore, as packaging and product variety are on a par with national brand equivalents, consumers continue to accept and be satisfied with private label products.

In-store clinics help drive retail sales

In the US there are a growing number of in-store clinics in drugstores, supermarkets, hypermarkets and mass merchandisers. Consumers are able to walk in to most clinics without an appointment and receive care for routine medical procedures like immunisations and throat cultures to test for strep throat. Retail clinics are often open later than doctors’ surgeries during the week, making it much more convenient for consumers to visit these clinics than visiting their physicians. Additionally, most insurance is accepted and if not, the rates are less than most physicians’ service fees. Retailers focusing on in-store clinics are experiencing stronger sales growth than channels without a consumer health focus. Adjacency to a pharmacy allows consumers to purchase prescriptions and other healthcare items immediately following a clinic visit.

Challenges threaten future industry growth

Factors like an ageing population undoubtedly bode well for the consumer health industry, and growth is expected over the forecast period. However, recent challenges threaten to pull future growth well below that of the review period. Firstly, Johnson & Johnson’s many recalls threaten to erode consumer confidence in the safety and efficacy of many OTC remedies. Secondly, regulatory discussions surrounding some of the most important active ingredients in OTC products threaten to make many products more difficult to obtain. Finally, the 2010 Patient Protection and Affordable Care Act prevents consumers from using flexible spending account (FSA) dollars to purchase OTC products (unless they have a prescription), starting in January 2011. The new law also increases prescription drug access, potentially eroding markets where OTC remedies had been used in the past. These many new challenges threaten to hinder the future performance of the industry at a time filled with tremendous potential.

Table of Contents

Table of Contents

Consumer Health in the US - Industry Overview

EXECUTIVE SUMMARY

Consumer health industry remains vital

Market leader hit by series of product recalls

Private label growth continues

In-store clinics help drive retail sales

Challenges threaten future industry growth

KEY TRENDS AND DEVELOPMENTS

Johnson & Johnson initiates a series of major product recalls

Debate surrounds the abuse potential of major drugs

US passes landmark healthcare reform law

Ageing population drives growth through OTC, vitamins and dietary supplements and sports nutrition

Retail health clinics continue to grow

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2005-2010
  • Table 2 Life Expectancy at Birth 2005-2010

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2005-2010
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2005-2010
  • Table 5 Consumer Health Company Shares by Value 2006-2010
  • Table 6 Consumer Health Brand Shares by Value 2007-2010
  • Table 7 Penetration of Private Label by Category 2005-2010
  • Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2005-2010
  • Table 9 Sales of Consumer Health by Category and Distribution Format: % Analysis 2010
  • Table 10 Forecast Sales of Consumer Health by Category: Value 2010-2015
  • Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2010-2015

APPENDIX

OTC Registration and Classification

Vitamins and Dietary Supplements Registration and Classification

Self-medication/self-care and Preventative Medicine

Switches

  • Summary 1 OTC Healthcare Switches 2008-2010

DEFINITIONS

  • Summary 2 Research Sources

Consumer Health in the US - Company Profiles

Adams Respiratory Therapeutics Inc - Consumer Health - USA

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 4 Adams Respiratory Therapeutics Inc: Competitive Position 2010

Bayer Corp - Consumer Health - USA

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 6 Bayer Corp: Competitive Position 2010

Chattem Inc - Consumer Health - USA

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 9 Chattem Inc: Competitive Position 2010

General Nutrition Centers Inc - Consumer Health - USA

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 12 General Nutrition Centers Inc: Competitive Position 2010

GlaxoSmithKline Consumer Health - Consumer Health - USA

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 14 GlaxoSmithKline Consumer Health: Competitive Position 2010

McNeil Consumer & Specialty Pharmaceuticals - Consumer Health - USA

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 16 McNeil Consumer & Specialty Pharmaceuticals: Competitive Position 2010

Melaleuca Inc - Consumer Health - USA

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 18 Melaleuca Inc: Competitive Position 2010

Nature's Sunshine Products Inc - Consumer Health - USA

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 21 Nature’s Sunshine Products Inc: Competitive Position 2010

Pfizer Consumer Healthcare Inc - Consumer Health - USA

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 23 Pfizer Consumer Healthcare Inc: Competitive Position 2010

Wal-Mart Stores Inc - Consumer Health - USA

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 25 Wal-Mart Stores: Competitive Position 2010

Adult Mouth Care in the US - Category Analysis

HEADLINES

TRENDS

  • In 2010, adult mouth care witnessed little innovation or new developments. Del Pharmaceuticals, the category’s leading player, released a variety of new products in 2010 including new Baby Orajel SmartDose, Orajel Toddler Training Toothpastes and Orajel Instant Cold Sore Relief. However, none of these new Orajel releases fall under Euromonitor International’s adult mouth care category. With no new innovations in the category, adult mouth care sales were generally flat in 2010, following the general direction of the US economy after a dip in sales during the recession in 2009.

COMPETITIVE LANDSCAPE

  • Del Pharmaceuticals continued to lead adult mouth care in 2010 with a 35% value share. The company is the leader in the toothache segment, with a smaller presence in adult dry mouth and canker sore treatments. Del Pharmaceuticals has remained a dynamic player in the category despite changing hands twice since 2007. In the summer of 2008, it was acquired by Church & Dwight, which is eagerly looking to integrate the brand’s strong growth opportunities into its portfolio of mid-tier brands. Pfizer, the category’s number two player, saw its value share rise to 14% in 2010 thanks to the strong performance of its Anbesol brand.

PROSPECTS

  • Adult mouth care is expected to grow by 3% in constant value terms over 2010-2015. Oral pain products will benefit from the continuing ageing of the US population, which will need pain relief from dentures or heavy dental work. The increase in number of older consumers, who are more likely to take medication regularly, will also benefit mouth moisturisers. The recent acquisition activity in the category suggests that manufacturers are seeing strong growth opportunities in this niche. However, some of the gains in the oral pain segment will come at the expense of smaller and less innovative players rather than actual industry growth. Furthermore, the potential for growth will be offset by the continued emergence of cheaper private label alternatives, which will steadily gain share over the forecast period.

CATEGORY DATA

  • Table 12 Sales of Adult Mouth Care: Value 2005-2010
  • Table 13 Sales of Adult Mouth Care: % Value Growth 2005-2010
  • Table 14 Adult Mouth Care Company Shares by Value 2006-2010
  • Table 15 Adult Mouth Care Brand Shares by Value 2007-2010
  • Table 16 Forecast Sales of Adult Mouth Care: Value 2010-2015
  • Table 17 Forecast Sales of Adult Mouth Care: % Value Growth 2010-2015

Analgesics in the US - Category Analysis

HEADLINES

TRENDS

  • The key story in analgesics in 2010 was Johnson & Johnson’s recall of many major brands. In nearly every month from January to October, Johnson & Johnson instituted recalls affecting numerous lots of both children’s and adult Tylenol, Motrin and St Joseph products. The source of these recalls was a series of cGMP violations, and problems ranged from products having a musty or mouldy odour to liquid medications containing particulates. In an attempt to address these quality concerns, McNeil closed its manufacturing plant in Fort Washington, Pennsylvania and does not expect it to reopen it until mid-2011. As this plant was the only one that produced liquid children’s medications, many types of children’s Tylenol and Motrin products were not available on store shelves for most of 2010. These recalls caused major shifts in the analgesics category, ranging from a massive shift from consumers to private label products to questions about Johnson & Johnson’s reputation for product quality.

SWITCHES

COMPETITIVE LANDSCAPE

  • McNeil Consumer & Specialty Pharmaceuticals remained the leading company in analgesics in 2010. McNeil’s product line contains major brands in every category except naproxen. Its iconic Tylenol brand retained its position as the leading analgesic brand by value sales. Despite this position, however, the company’s sales were devastated by its recalls in 2010. A combination of product unavailability and losses of consumer trust brought the company’s sales down by 28% for 2010. Depending on how the company and consumers respond to the recalls, McNeil may never be able to return to its pre-recall position.

PROSPECTS

  • One major trend that will affect US analgesics is the country’s ageing and increasingly active population. These demographic and lifestyle patterns offer tremendous growth potential. This potential will be even greater for brands and products that position themselves as arthritis-specific. However, as these consumers continue to adopt a “toolkit” mentality to pain management, this potential will be limited. In this case, much of the potential gain for analgesic products may be forfeited to vitamins and dietary supplements, and other products related to holistic health and wellness.

CATEGORY DATA

  • Table 18 Sales of Analgesics by Category: Value 2005-2010
  • Table 19 Sales of Analgesics by Category: % Value Growth 2005-2010
  • Table 20 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2005-2010
  • Table 21 Analgesics Company Shares by Value 2006-2010
  • Table 22 Analgesics Brand Shares by Value 2007-2010
  • Table 23 Forecast Sales of Analgesics by Category: Value 2010-2015
  • Table 24 Forecast Sales of Analgesics by Category: % Value Growth 2010-2015

Calming and Sleeping in the US - Category Analysis

HEADLINES

TRENDS

  • In January 2010, Johnson & Johnson recalled nine lots of its leading brand Simply Sleep. The resulting lack of product availability and consumer scepticism devastated sales for the brand. Consumers responded by choosing private label alternatives, buying other brands and opting for alternative methods to help them sleep. Another possible option, selecting a night-time combination analgesic product, was also limited as Johnson & Johnson’s recalls affected that category as well.

COMPETITIVE LANDSCAPE

  • Chattem remained the leader in calming and sleeping in 2010 with a 24% value share. The company witnessed a significant share increase as consumers turned from unavailable Simply Sleep products to its Unisom line. McNeil remained in second place in 2010 as it was able to get some of its Simply Sleep products back onto the market after the January recall. However, the company’s value share dropped significantly in a year marked by major company recalls.

PROSPECTS

  • Numerous factors will contribute to a significant decline in this category over the forecast period. Firstly, many consumers who opted for alternative sleeping aids (ie non-medicated, prescription) during the 2010 recalls will stick with these remedies over the forecast period. In addition, the trend favouring natural remedies may dissuade consumers from purchasing medicated sleeping aids. Most importantly, the release of a new prescription product – Silenor (doxepin) – in 2010 will pose a serious threat to category growth. Silenor is different from any other Rx sleeping aid in that it is non-addictive, has few side effects and is the first non-controlled prescription sleeping aid product. This launch, in conjunction with millions of new Americans gaining health insurance coverage under healthcare reform, stands to take significant share from OTC sleeping aids. There is conjecture that Silenor may see a future Rx-to-OTC switch, but until then it stands to negatively affect OTC calming and sleeping sales. For these reasons, the category is forecast a constant value decline of 4% over 2010-2015.

CATEGORY DATA

  • Table 25 Sales of Calming and Sleeping: Value 2005-2010
  • Table 26 Sales of Calming and Sleeping: % Value Growth 2005-2010
  • Table 27 Calming and Sleeping Company Shares by Value 2006-2010
  • Table 28 Calming and Sleeping Brand Shares by Value 2007-2010
  • Table 29 Forecast Sales of Calming and Sleeping: Value 2010-2015
  • Table 30 Forecast Sales of Calming and Sleeping: % Value Growth 2010-2015

Cough, Cold and Allergy (Hay Fever) Remedies in the US - Category Analysis

HEADLINES

TRENDS

  • Two very important active ingredients in cough and cold products were the subject of heated regulatory discussion in 2010. Pseudoephedrine (PSE), a powerful decongestant, attracted criticism for its role in the illegal manufacture of methamphetamines, psychoactive stimulants that have a high propensity for addiction and abuse. The US government recognised this danger and passed the Combat Methamphetamine Epidemic Act (2006), which restricted sales of PSE and regulated the storage and record-keeping of the product. In 2010, however, the Consumer Healthcare Products Association (CHPA) called upon Congress to strengthen this act by requiring all PSE sales to be tracked in a nationwide E-tracking system. Many states have chosen to implement this type of system and two states – Oregon and Mississippi – have even “switched” PSE back to prescription-only status. Dextromethorphan (DXM), a key cough suppressant, has also been the subject of regulatory discussion for its major role in teenage drug abuse. In September, an FDA advisory committee voted 15-9 not to place DXM on the controlled substances schedule.

SWITCHES

COMPETITIVE LANDSCAPE

  • Johnson & Johnson, following the 2006 acquisition of Pfizer’s OTC business and the launch of Zyrtec, remained the category leader (in GBO terms) in 2010 with a 19% value share. The company’s leading position is tied to established brands such as Tylenol, Benadryl, Sudafed, and Zyrtec. The second major player in this category is Merck/Schering-Plough with an 11% value share, split between major brands such as Claritin, Afrin and Coricidin. Finally, Reckitt Benckiser/Adams Respiratory Therapeutics ranked third in 2010, also with an 11% share, through its flagship brands Mucinex and Delsym.

PROSPECTS

  • Future category growth is expected to be driven by potential Rx-to-OTC switches of Allegra and Clarinex. Both products are expected to lose Rx market exclusivity in the latter part of the forecast period, which typically signals a potential switch date to OTC status. However, recent developments suggest that the switches of both of these products will come sooner rather than later. In February 2010, pharmaceutical giant Sanofi-Aventis acquired Chattem in order to gain a solid foothold in the US OTC category. One month later, Sanofi submitted an application for an Rx-to-OTC switch for Allegra. This prescription antihistamine could complete the switch to OTC shelves in the next year or two. Allegra will face stiff competition as it enters a very crowded allergy remedies category. However, this product has a large prescription base with US sales of over US$660 million, and for this reason it is estimated that the product could make from US$150-200 million annually over the counter.

CATEGORY DATA

  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 32 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 33 Sales of Decongestants by Category: Value 2005-2010
  • Table 34 Sales of Decongestants by Category: % Value Growth 2005-2010
  • Table 35 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 36 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2006-2010
  • Table 38 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2007-2010
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2010-2015
  • Table 40 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2010-2015

Digestive Remedies in the US - Category Analysis

HEADLINES

TRENDS

  • In 2010, competition between major players in indigestion and heartburn categories intensified dramatically. The battle to win consumers stemmed from two Rx-to-OTC switches within proton pump inhibitors (PPIs) within a span of only five months. In November 2009, Novartis launched Prevacid 24hr and supported it with the largest advertising campaign in the company’s history. Schering-Plough followed by releasing its own Rx-to-OTC PPI – Zegerid OTC – in April 2010. Expectations were high for both products. Prevacid’s massive pre-switch prescription base led to estimates of the brand breaking US$200 million in annual sales in its first year, while Zegerid’s smaller Rx base led to estimates of around US$100 million for first-year sales. The threat of these giant new brands and their advertising led previously established players in related categories to retaliate with new advertising campaigns of their own. Procter & Gamble’s Prilosec – the first PPI to switch from Rx-to-OTC – launched a new advertising initiative, and other antacids like Tums followed suit. In fact, this intensified competition drove advertising spend to record-levels in 2010.

SWITCHES

COMPETITIVE LANDSCAPE

  • Procter & Gamble remained the leader in digestive remedies with its major brands like Pepto-Bismol, Metamucil and Prilosec, retaining an overall value share of 17% in 2010. GlaxoSmithKline, led by its Tums brand, held the second overall rank in the category with an 8% value share in 2010. Third-ranked in 2010 was McNeil with a 7% value share held through major brands like Imodium, Rolaids and Lactaid.

PROSPECTS

  • Digestive remedies should continue to be shaped by the development of the PPI category. The intense competition for customers from the three major branded PPIs (Prilosec, Prevacid and Zegerid) should continue to drive high levels of advertising and push sales upwards. In addition, there is a possibility that Pfizer’s Protonix and Eisai’s Aciphex – two other PPIs – could go through an Rx-to-OTC switch in the future. These potential switches stand to bring more consumers into the PPI category and drive sales even further. Finally, PPIs could see a bigger boost from healthcare reform in the US in 2010. As millions of previously uninsured Americans gain access to healthcare, many will see a doctor about heartburn instead of just taking traditional antacid products. As PPI sales are driven largely by doctor recommendations, an increase in visits to doctors should translate into higher rates of PPI usage to treat frequent heartburn. For all of these reasons, Euromonitor International forecasts constant value growth of 16% over 2010-2015 for the PPI category. This growth could be even higher; however, the rapid growth of cheaper private label PPIs threatens to erode value sales. Many retailers have begun to offer omeprazole PPIs as part of their private label product lines. A similar fate is also likely for lansoprazole (Prevacid) in the near future. Private label already holds a 25% value share of the category, a share that will likely grow quite rapidly over the forecast period.

CATEGORY DATA

  • Table 41 Sales of Digestive Remedies by Category: Value 2005-2010
  • Table 42 Sales of Digestive Remedies by Category: % Value Growth 2005-2010
  • Table 43 Digestive Remedies Company Shares by Value 2006-2010
  • Table 44 Digestive Remedies Brand Shares by Value 2007-2010
  • Table 45 Forecast Sales of Digestive Remedies by Category: Value 2010-2015
  • Table 46 Forecast Sales of Digestive Remedies by Category: % Value Growth 2010-2015

Ear Care in the US - Category Analysis

HEADLINES

TRENDS

  • In 2010, ear care players launched a series of new marketing and advertising initiatives aimed at driving sales growth. During the summer, ear care companies catering to swimmers intensified their marketing efforts. Health Enterprises, for example, benefited from celebrity endorsement from Megan Jendrick, an Olympic gold medallist, for its AfterSwim and Swim-Fit products in June. In May, Insight Pharmaceuticals sought to market its Auro-Dri brand by sponsoring the World’s Largest Swimming Lesson. Other companies have even taken up marketing on YouTube and Facebook. Although these products do not all fit Euromonitor International’s definition of ear care products, these marketing campaigns served to increase awareness of ear remedies and drive sales up across the entire category.

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline remained the leader in ear care in 2010 with its Debrox brand. The company’s value share stood at 36%, up from 2009 given Debrox’s success in 2010. Private label players also gained share, bringing the overall value share of private label ear care products to 33% in 2010. Prestige Brands, another major player in the category with its Murine brand, saw its value share dip in 2010 to 18%.

PROSPECTS

  • As the economy recovers, ear care should continue to resume its healthy pre-recession pattern of growth. In addition, new and innovative marketing campaigns will serve to drive category awareness and increase sales over the forecast period. Euromonitor International projects healthy growth of 6% in constant value terms over 2010-2015.

CATEGORY DATA

  • Table 47 Sales of Ear Care: Value 2005-2010
  • Table 48 Sales of Ear Care: % Value Growth 2005-2010
  • Table 49 Ear Care Company Shares by Value 2006-2010
  • Table 50 Ear Care Brand Shares by Value 2007-2010
  • Table 51 Forecast Sales of Ear Care: Value 2010-2015
  • Table 52 Forecast Sales of Ear Care: % Value Growth 2010-2015

Emergency Contraception in the US - Category Analysis

HEADLINES

TRENDS

  • In August 2009, the FDA approved Watson Pharmaceuticals’ Next Choice emergency contraceptive for OTC sale. The drug is the generic bioequivalent of Plan B, and as Next Choice is priced 10-20% lower than Plan B, its sales took off as soon as it hit the market. In fact, by the end of 2010, sales of Next Choice in its first full year on the market surpassed those of Plan B to make Watson the new category leader.

COMPETITIVE LANDSCAPE

  • In its first full-year on the market, sales of Next Choice drove Watson Pharmaceuticals to the top spot in the category with a 52% value share in 2010. Duramed Pharmaceuticals, previously the only player in the category, subsequently saw its share fall dramatically. However, its loss would have been even greater without the success of the company’s Plan B One Step, which caters for those who value convenience.

PROSPECTS

  • In August 2010, the FDA approved Ella, a new prescription emergency contraceptive that is likely to dramatically influence the future of the OTC channel. Ella (ulipristal acetate) plays on consumer demand for added convenience by claiming that it can prevent pregnancy when taken orally within 120 hours (five days) of unprotected sex. Currently, Next Choice, Plan B and Plan B One Step must be used as soon as possible and are no longer effective if taken more than 72 hours after unprotected sex. This product is looking to take the “emergency” out of emergency contraception and give women more flexibility.

CATEGORY DATA

  • Table 53 Sales of Emergency Contraception: Value 2006-2010
  • Table 54 Sales of Emergency Contraception: % Value Growth 2006-2010
  • Table 55 Emergency Contraception Company Shares by Value 2006-2010
  • Table 56 Emergency Contraception Brand Shares by Value 2007-2010
  • Table 57 Forecast Sales of Emergency Contraception: Value 2010-2015
  • Table 58 Forecast Sales of Emergency Contraception: % Value Growth 2010-2015

Eye Care in the US - Category Analysis

HEADLINES

TRENDS

  • In 2010, a combination of factors came together to produce strong growth in eye care. Firstly, high rates of dry eye and contact lens usage kept demand high for standard eye care products. Secondly, Bausch & Lomb’s launch of Biotrue, an innovative new contact lens solution, brought a host of new marketing and advertising to the eye care category. Although Euromonitor International does not cover contact lens solutions in its eye care category, this new product launch increased consumer awareness of general eye health and brought new customers to the eye care aisle. Thirdly, an ageing population in the US naturally pulled people into the category in search of dry eye relief. All of these factors combined to form a perfect storm in which eye care delivered a strong sales increase in 2010.

COMPETITIVE LANDSCAPE

  • Alcon Laboratories remained the category leader in 2010 with a 21% value share thanks to major brands like Naphcon and Systane. Alcon also saw the one of the largest share gains in the category in 2010 thanks to the strong performance of its Systane dry eye products, particularly its Systane Ultra brand. Bausch & Lomb, Allergan and McNeil are also major players in the eye care category. Although each of these players command a value share of over 10%, they all lost share in 2010.

PROSPECTS

  • Many of the factors contributing to the current success of standard eye care also bode well for a strong future performance. Factors like an ageing population will be complemented by the increased use of prescription medications (a leading cause of dry eye) under US healthcare reform. Euromonitor International forecasts that contact lens sales in the US should more than double over the forecast period, providing tremendous potential for dry eye remedies. Even demographic patterns like rapid population growth in the southern regions of the US – areas with drier and dustier climates – provide a promising picture for the future of dry eye remedies within the standard eye care category. For these reasons, standard eye care is expected to register strong constant value growth of 8% over 2010-2015.

CATEGORY DATA

  • Table 59 Sales of Eye Care by Category: Value 2005-2010
  • Table 60 Sales of Eye Care by Category: % Value Growth 2005-2010
  • Table 61 Standard Eye Care by Type: % Value Breakdown 2007-2010
  • Table 62 Eye Care Company Shares by Value 2006-2010
  • Table 63 Eye Care Brand Shares by Value 2007-2010
  • Table 64 Forecast Sales of Eye Care by Category: Value 2010-2015
  • Table 65 Forecast Sales of Eye Care by Category: % Value Growth 2010-2015

Herbal/Traditional Products in the US - Category Analysis

HEADLINES

TRENDS

  • Herbal/traditional products remains a niche but rapidly developing area of self-medication in the US. Around 68% of overall value sales were accounted for by herbal/traditional dietary supplements in 2010, with the remainder being herbal/traditional alternatives to allopathic OTC healthcare. Within this, herbal/traditional products are largely found in cough, cold and allergy (hay fever) remedies and digestive remedies. The medicinal benefits of ingredients such as menthol as a cough suppressant and natural fibre as a laxative are well documented and accepted by US consumers. Certain natural fibres such as psyllium husk carry US FDA approval to be marketed as an OTC constipation treatment, with such product claims not being permitted for most herbal/traditional products.

COMPETITIVE LANDSCAPE

  • Cadbury Adams USA LLC was the leading player in herbal/traditional products in 2010 with a 7% value share. The company’s strength in the category is linked to its Halls medicated confectionery brand. The products appeal to US consumers as inexpensive immediate relief from sore throats and coughs. The brand is notoriously ubiquitous and can be found in drugstores, mass merchandisers, supermarkets, convenience stores and most other retail channels where medication or confectionery is sold.

PROSPECTS

  • Herbal/traditional products is expected to post a 1% constant value CAGR over the forecast period, which will be slightly lower than the performance of the consumer health industry as a whole. Demand for natural health treatments will remain strong, yet the majority of growth in US consumer health will be driven by apathic OTC remedies, specifically future Rx-to-OTC switches.

CATEGORY DATA

  • Table 66 Sales of Herbal/Traditional Products: Value 2005-2010
  • Table 67 Sales of Herbal/Traditional Products: % Value Growth 2005-2010
  • Table 68 Herbal/Traditional Products Company Shares 2006-2010
  • Table 69 Herbal/Traditional Products Brand Shares 2007-2010
  • Table 70 Forecast Sales of Herbal/Traditional Products: Value 2010-2015
  • Table 71 Forecast Sales of Herbal/Traditional Products: % Value Growth 2010-2015

Medicated Skin Care in the US - Category Analysis

HEADLINES

TRENDS

  • Guthy-Renker’s Proactiv acne system – the leader in acne treatments – has seen unparalleled competition in recent years. In addition to the many types of acne products sold in national retailers, products like Neutrogena SkinID and Stiefel’s MaxClarity threatened the direct-to-consumer channel in which Proactiv has thrived. For this reason, Proactiv dramatically intensified its marketing efforts in 2010. In January, the brand signed celebrities Katy Perry, Jenna Fischer and Avril Lavigne to multi-million dollar contracts as spokespeople for Proactiv products. In August, teen pop sensation Justin Bieber also signed as a Proactiv spokesperson for a 2-year deal worth US$3 million. Guthy-Renker also increased its spending on advertising for Proactiv. First quarter 2010 short-form direct response television advertising spend for Proactiv increased by more than 35% from the fourth quarter of 2009 and by over 64% from a year ago. This massive new advertising initiative forced all other players in acne treatments to focus intensively on brand/product differentiation as they sought to compete effectively and retain their respective shares.

SWITCHES

COMPETITIVE LANDSCAPE

  • Johnson & Johnson continued to lead medicated skin care in 2010 (in GBO terms) with a 28% value share. The company’s leadership is the result of an amalgamation of several unrelated business units. The bulk of the company’s sales come from the Pfizer consumer healthcare acquisition, most notably brands like Rogaine and Neosporin. Johnson & Johnson is also a leading player in acne treatments and medicated shampoos with its Neutrogena brand. Neutrogena is a respected skin care brand that has successfully managed to span both medicated and beauty skin care. The company is also the leading player in vaginal antifungals, with its Monistat brand commanding a 50% value share in 2010.

PROSPECTS

  • Medicated skin care in the US is very mature, with limited potential for future switches. For this reason, the category is expected to register slow constant value growth of 2% over 2010-2015. Demand for nappy rash treatments, cold sore treatments, topical antiseptics and topical and vaginal antifungals will remain consistent over the forecast period. In these categories, there should be little improvement in the technology and ingredients that are used, providing a situation that is ripe for private label manufacturers to grow at the expense of branded players.

CATEGORY DATA

  • Table 72 Sales of Medicated Skin Care by Category: Value 2005-2010
  • Table 73 Sales of Medicated Skin Care by Category: % Value Growth 2005-2010
  • Table 74 Acne Treatments by Format: % Value Breakdown 2005-2010
  • Table 75 Medicated Skin Care Company Shares by Value 2006-2010
  • Table 76 Medicated Skin Care Brand Shares by Value 2007-2010
  • Table 77 Acne Treatments Brand Shares by Value 2007-2010
  • Table 78 Hair Loss Treatments Brand Shares by Value 2007-2010
  • Table 79 Forecast Sales of Medicated Skin Care by Category: Value 2010-2015
  • Table 80 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2010-2015

NRT Smoking Cessation Aids in the US - Category Analysis

HEADLINES

TRENDS

  • In April 2010, GlaxoSmithKline brought significant innovation to the NRT smoking cessation aids category with the launch of its Nicorette Mini Lozenge. This product is significantly smaller and dissolves three times faster than traditional lozenges currently on the market. In addition, these “mini lozenges” are sold in three small vials containing 27 lozenges each, a packaging format that both maximises portability and ensures discreet usage. This innovation had an effect on both the overall direction of NRT smoking cessation aids and the performance of various categories.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline (GSK) remained the category leader in 2010 with a 52% value share. Over the review period private label competitors worked to slowly erode GSK’s leading position from a value share of over 70% in 2002. Recent innovations, however, have worked to dramatically slow the progress of private label. In NRT gum, for example, the company launched Nicorette White Ice Mint in 2008, which promised to whiten teeth – a welcome benefit for would-be quitters with tar-stained teeth. This product, coupled with Nicorette Cinnamon Surge, launched in late 2007, has helped to slow GSK’s share decline in NRT gum. In 2010, GSK still held a 51% value share in NRT gum, but will need to work towards further innovation if it is to maintain its share.

PROSPECTS

  • NRT smoking cessation aids has tremendous potential for growth over the forecast period. Firstly, it is estimated that 16% of the adult population in the US still smoke. As the federal and state governments continue to levy smoking tax increases and enact public smoking bans, the pressure on smokers to quit will increase. In addition, as educational efforts make the public increasingly aware of the myriad of health problems that stem from smoking, quitting should become increasingly popular. Finally, the growing preoccupation with healthier lifestyle choices and holistic wellness among US consumers and in the American educational system should continue to encourage people of all ages to quit smoking. Euromonitor International estimates that the percentage of the adult smoking population in the US should fall from 16.2% to 14.8% over the forecast period.

CATEGORY INDICATORS

  • Table 81 Number of Smokers by Gender 2005-2010

CATEGORY DATA

  • Table 82 Sales of NRT Smoking Cessation Aids by Category: Value 2005-2010
  • Table 83 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2005-2010
  • Table 84 NRT Gum Flavours: % Value Breakdown 2006-2010
  • Table 85 NRT Smoking Cessation Aids Company Shares by Value 2006-2010
  • Table 86 NRT Smoking Cessation Aids Brand Shares by Value 2007-2010
  • Table 87 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2010-2015
  • Table 88 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2010-2015

Sports Nutrition in the US - Category Analysis

HEADLINES

TRENDS

  • Sports nutrition remains extremely relevant to core users of products in this category. Although the recession caused many Americans to cut back on their spending and purchase replacement products for many of their needs, sports nutrition enthusiasts were not as likely to reduce or eliminate spending in this category. In addition to devoted users, general consumers are also entering the category as distribution of sports nutrition products becomes more mainstream. Furthermore, as obesity remains on the rise in the US, consumers are focusing on health, exercising more and looking for ways to supplement their workouts. They are also more interested in over-the-counter products such as vitamins, dietary supplements and sports nutrition products used as preventative measures and prefer to avoid visiting their doctors.

COMPETITIVE LANDSCAPE

  • Abbott Laboratories’ EAS line of sports nutrition led sales in 2010 with a 14% value share. Its Myoplex brand is very popular in the US and has products in a variety of formats appealing to many different consumers. Other EAS product lines include AdvantEdge, Pro Science and EAS Specialty. Many EAS products are aligned with celebrities including Chase Utley of the Philadelphia Phillies baseball team, Danny Granger of the Indiana Pacers basketball team, Larry Fitzgerald of the Arizona Cardinals football team, Mark Weir a mountain bicyclist and Charles Howell III, a professional golfer. Consumers are often swayed by celebrity endorsements or desire products that athletes support. Many of the products are certified by professional sports organisations, indicating that they do not contain banned substances, further contributing to greater consumer acceptance of EAS products.

PROSPECTS

  • Sports nutrition is expected to post a constant value CAGR of 3% over the forecast period. With two-thirds of US consumers being obese or overweight and wanting to lose weight, sports nutrition companies are expected to benefit from assisting these consumers with their overall quest for fitness. Additionally, other consumers who are not overweight but are also taking a proactive approach to health will also seek the benefits of sports nutrition products to enhance their workouts and improve their overall endurance. Given the underdeveloped nature of sports nutrition in mass retailers and the large number of consumers that can benefit from sports nutrition, manufacturers that make a push into mass retail channels over the forecast period are expected to experience wide consumer acceptance.

CATEGORY DATA

  • Table 89 Sales of Sports Nutrition: Value 2005-2010
  • Table 90 Sales of Sports Nutrition: % Value Growth 2005-2010
  • Table 91 Sports Nutrition By Format: % Value Breakdown 2007-2010
  • Table 92 Sports Nutrition Company Shares 2006-2010
  • Table 93 Sports Nutrition Brand Shares 2007-2010
  • Table 94 Forecast Sales of Sports Nutrition: Value 2010-2015
  • Table 95 Forecast Sales of Sports Nutrition: % Value Growth 2010-2015
  • Table 96 Sports Nutrition: Brand Ranking

Vitamins and Dietary Supplements in the US - Category Analysis

HEADLINES

TRENDS

  • The US vitamins and dietary supplements category withstood the recession and continued to grow in 2010. While most other consumer categories experienced declines or slower sales growth, vitamins and dietary supplements actually performed better in 2010 than in 2009. The strong demand for vitamins and dietary supplements was driven by several factors, including healthcare costs continuing to rise and the growing health and wellness trend.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • NBTY Inc led vitamins and dietary supplements in the US in 2010 with a 6% value share. The company’s strength comes from its unique vertical integration, with separate divisions involved in the manufacturing, distribution and retailing of its vitamins and dietary supplements. It is also the only player that is active in all distribution channels. Its Nature’s Bounty and Sundown brands are sold through mass channels, while Solgar can be found in health food shops. The company is also present in non-store retailing, with an internet and catalogue order business for brands including Puritan’s Pride. The company also has a national chain of health food shops which sell the company’s Vitamin World brand and other third-party products. In addition to its retail, branded and direct sales business, NBTY acquired Leiner Health in 2008, a leading manufacturer of private label vitamins and dietary supplements. According to the company’s own estimates, Leiner accounted for approximately 50% of all private label vitamins and dietary supplements in the US. The company’s mass business offers NBTY attractive manufacturing economies of scale, while its higher-end products deliver higher margins. NBTY also benefits from its direct interaction with consumers through mail order.

PROSPECTS

  • Vitamins and dietary supplements in the US is expected to grow by 16% in constant value terms over 2010-2015. Several factors and categories will help drive this growth. By 2015, 28% of the US population will be 50-years-old or above, compared to 26% in 2010. The ageing population will add to the number of heavy users of vitamins and dietary supplements due to greater incidence of age-related ailments. Additionally, low household penetration across many product categories means there are many consumers who are currently not taking vitamins and dietary supplements but could benefit from doing so.

CATEGORY DATA

  • Table 97 Sales of Vitamins and Dietary Supplements by Category: Value 2005-2010
  • Table 98 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2005-2010
  • Table 99 Dietary Supplements by Positioning 2005-2010
  • Table 100 Vitamins and Dietary Supplements Company Shares by Value 2006-2010
  • Table 101 Vitamins and Dietary Supplements Brand Shares by Value 2007-2010
  • Table 102 Vitamins Brand Shares by Value 2007-2010
  • Table 103 Dietary Supplements Brand Shares by Value 2007-2010
  • Table 104 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2010-2015
  • Table 105 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2010-2015
  • Table 106 Dietary Supplements: Brand Ranking by Positioning 2010

Weight Management in the US - Category Analysis

HEADLINES

TRENDS

  • In 2010, weight management was still reeling from a series of major recalls from the previous year that left many consumers sceptical about the quality and efficacy of these products. These recalls began in February 2009 when Slim-Fast Foods had to recall some of its meal replacement bars as they contained contaminated peanuts that could lead to an outbreak of salmonella. Three months later, this recall was dwarfed by the recall of Hydroxycut – one of the top selling weight loss supplements only one year earlier. This May recall stemmed from the link between Hydroxycut and 23 serious liver injuries and one death. Although the FDA was unable to find the specific ingredient causing the problems, the recall damaged how consumers perceived weight loss products. This reputation was further devastated by another massive recall in December 2009 of Slim Fast ready-to-drink shakes. In this case, over 10 million cans of Slim Fast were recalled due to potential contamination with a bacteria called Bacillus cereus that can lead to nausea, vomiting and diarrhoea. As consumers examined their weight loss options in 2010, many opted to avoid meal replacements and supplements in favour of a healthy diet, exercise and holistic approaches to health and wellness. The series of recalls in 2009 cast significant doubts over the safety and desirability of these weight management products, and value sales dropped by 3% in current terms in 2010 as a result.

COMPETITIVE LANDSCAPE

  • Herbalife, the leader in weight management, further cemented its position at the top of the category with another strong performance in 2010. The company’s continued success in the US has been driven by its focus on the Hispanic community and the expansion of its globally successful Nutrition Club concept, which originated in Latin America. According to Herbalife, Latino consumers accounted for 69% of the company’s sales in 2009 compared to 37% in 2004. The CDC reports that the incidence of obesity is higher among Hispanic children and adults than among the rest of the population, making this demographic group particularly attractive to the company. In 2006, the company transformed itself, shifting from an equal focus on vitamins and dietary supplements and slimming products to focusing primarily on weight loss products. The strength of the company’s Nutrition Club concept is that its weight loss supplements and meal replacement slimming products are promoted as a holistic daily solution to maintaining a healthy weight, rather than the quick-fix promise offered by other products. Herbalife positions its flagship Formula 1 shake as a healthier and value-priced alternative to consumer foodservice.

PROSPECTS

  • There is no doubt that demand for weight management products will remain high over the forecast period. Between 2010 and 2014, Euromonitor International projects that the share of the adult population that is obese will rise by over three percentage points to 43.4% of the US population. This represents a tremendous opportunity for these types of products.

CATEGORY DATA

  • Table 107 Sales of Weight Management: Value 2005-2010
  • Table 108 Sales of Weight Management: % Value Growth 2005-2010
  • Table 109 Weight Management Company Shares 2006-2010
  • Table 110 Weight Management Brand Shares 2007-2010
  • Table 111 Forecast Sales of Weight Management: Value 2010-2015
  • Table 112 Forecast Sales of Weight Management: % Value Growth 2010-2015

Wound Care in the US - Category Analysis

HEADLINES

TRENDS

  • In 2010, Medline Industries, a small company in the category, launched a series of product innovations that helped it capture significant share gains and drive overall sales in the category. Upon acquiring the Curad brand in 2007, Medline Industries worked to expand the brand beyond its traditional bandage product line into all areas of wound care and first aid. For example, products like Curad Hold Tite, Waterproof Blister Heal Bandages, Flex-Fabric Bandage Travel Packs and even children’s Camouflage Adhesive Bandages are all recent Medline innovations. These new products helped Curad’s sales grow by nearly 40% in 2010 and also helped drive sales for the entire category.

COMPETITIVE LANDSCAPE

  • Johnson & Johnson remained category leader in 2010 with a 37% value share. Its iconic Band-Aid brand has become a generic term, with many US consumers referring to any sticking plaster as a “Band-Aid”. Despite continued promotional efforts, the company continues to lose share to low-priced private label products.

PROSPECTS

  • The category is set to remain flat over the forecast period. Wound care is highly commoditised and has virtually 100% household penetration. Even though Medline, Johnson & Johnson and 3M will seek to drive growth through product innovation, private label will be quick to copy these new product developments and sell them at lower price points, thus depressing value growth.

CATEGORY DATA

  • Table 113 Sales of Wound Care by Category: Value 2005-2010
  • Table 114 Sales of Wound Care by Category: % Value Growth 2005-2010
  • Table 115 Wound Care Company Shares by Value 2006-2010
  • Table 116 Wound Care Brand Shares by Value 2007-2010
  • Table 117 Forecast Sales of Wound Care by Category: Value 2010-2015
  • Table 118 Forecast Sales of Wound Care by Category: % Value Growth 2010-2015

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Child-Specific Analgesics
            • Child-Specific Acetaminophen
            • Child-Specific Aspirin
            • Child-Specific Combination Products - Analgesics
            • Child-Specific Diclofenac
            • Child-Specific Dipyrone
            • Child-Specific Ibuprofen
            • Child-Specific Ketoprofen
            • Child-Specific Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Child-Specific Cough, Cold and Allergy Remedies
          • Child-Specific Allergy Remedies
          • Child-Specific Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Child-Specific Digestive Remedies
          • Child-Specific Diarrhoeal Remedies
          • Child-Specific Indigestion and Heartburn Remedies
          • Child-Specific Laxatives
          • Child-Specific Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Acne Treatments
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Child-Specific Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
    • Vitamins and Dietary Supplements
      • Child-Specific Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Fibre
            • Green Tea Extract
            • Isoflavones
            • Mangosteen Juice
            • Noni
            • Saw Palmetto
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
        • Tonics and Bottled Nutritive Drinks
        • Vitamins
          • Multivitamins
          • Single Vitamins
            • Vitamin A
            • Vitamin B
            • Vitamin C
            • Vitamin D
            • Vitamin E
            • Other Single Vitamins
      • Weight Management
        • Meal Replacement Slimming
        • OTC Obesity
        • Slimming Teas
        • Weight Loss Supplements
        • Other Slimming Products
      • Herbal/Traditional Products
        • Herbal/Traditional Analgesics
        • Herbal/Traditional Calming and Sleeping Products
        • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
        • Herbal/Traditional Digestive Remedies
        • Herbal/Traditional Medicated Skin Care
        • Herbal/Traditional Medicinal Teas
        • Herbal/Traditional Smoking Cessation Aids
        • Herbal/Traditional Child-Specific Dietary Supplements
        • Herbal/Traditional Dietary Supplements
        • Herbal/Traditional Tonics and Bottled Nutritive Drinks
      • Allergy Care
        • Allergy Eye Care
        • Antihistamines/Allergy Remedies (Systemic)
        • Child-Specific Allergy Remedies
        • Topical Allergy Remedies/Antihistamines
      • Child-Specific Consumer Health
        • Child-Specific Analgesics
          • Child-Specific Acetaminophen
          • Child-Specific Aspirin
          • Child-Specific Combination Products - Analgesics
          • Child-Specific Diclofenac
          • Child-Specific Dipyrone
          • Child-Specific Ibuprofen
          • Child-Specific Ketoprofen
          • Child-Specific Naproxen
        • Child-Specific Cough, Cold and Allergy Remedies
          • Child-Specific Allergy Remedies
          • Child-Specific Cough/Cold Remedies
        • Child-Specific Digestive Remedies
          • Child-Specific Diarrhoeal Remedies
          • Child-Specific Indigestion and Heartburn Remedies
          • Child-Specific Laxatives
          • Child-Specific Motion Sickness Remedies
        • Child-Specific Medicated Skin Care
        • Nappy (Diaper) Rash Treatments
        • Child-Specific Vitamins and Dietary Supplements

    Statistics Included

    Statistics Included

    For each category and subcategory you will receive the following data in Excel format:

    From Passport

    • Market Sizes
    • Company Shares
    • Brand Shares
    • Distribution
    • Analysis by Format
    • Analysis by Positioning
    • Analysis by Type
    • Herbal/Traditional vs Standard
    • Pricing

    Market size details:

    • Retail Volume
    • Retail Volume % growth
    • Retail Volume per capita
    • Retail Value retail selling price % growth
    • Retail Value retail selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail Value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail Value retail selling price real (constant 2008) Prices % growth
    • Retail Value retail selling price real (constant 2008) Prices local currency, USD, EUR, GBP, CHF, JPY
    • Retail Value retail selling price real (constant 2008) Prices per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail Value manufacturer selling price % growth
    • Retail Value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail Value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail Value manufacturer selling price real (constant 2008) Prices % growth
    • Retail Value manufacturer selling price real (constant 2008) Prices local currency, USD, EUR, GBP, CHF, JPY
    • Retail Value manufacturer selling price real (constant 2008) Prices per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail Value retail selling price Nominal (Current) Prices % growth
    • Retail Value retail selling price Nominal (Current) Prices local currency, USD, EUR, GBP, CHF, JPY
    • Retail Value retail selling price Nominal (Current) Prices per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail Value manufacturer selling price Nominal (Current) Prices % growth
    • Retail Value manufacturer selling price Nominal (Current) Prices local currency, USD, EUR, GBP, CHF, JPY
    • Retail Value manufacturer selling price Nominal (Current) Prices per capita local currency, USD, EUR, GBP, CHF, JPY

    Methodology

    Methodology

    Global insight and local knowledge

    With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

    This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

    Industry specialists

    Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

    Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

    The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

    Country and regional analysts

    Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

    In-country research network

    To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

    Research Methodology

    Our research methods

    Each Euromonitor International industry report is based on a core set of research techniques:

    Desk research

    With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

    • National statistics offices governmental and official sources
    • National and international trade press
    • National and international trade associations
    • Industry study groups and other semi-official sources
    • Company financials and annual reports
    • Broker reports
    • Online databases
    • The financial, business and mainstream press

    Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

    Store checks

    Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

    • Place: We track products in all relevant channels, selective and mass, store and non-store
    • Product: What are innovations in products, pack sizes and formats?
    • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
    • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

    Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

    Trade survey

    Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

    Trade surveys allow us to:

    • Fill gaps in available published data per company
    • Generate a consensus view of the size, structure and strategic direction of the category
    • Access year-in-progress data where published sources are out of date
    • Evaluate the experts’ views on current trends and market developments

    In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

    Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

    Company analysis

    At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

    At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

    Forecasts

    Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

    Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

    Data validation

    All data is subjected to an exhaustive review process, at country, regional and global levels.

    The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

    Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

    Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

    Market analysis

    Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

    Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

    my pages

    Want to find out more about this report?